Butterfly Network’s iQ3™ Honored as the Best Medical Technology at 2024 Prix Galien USA Awards
Butterfly Network's iQ3™ handheld ultrasound device has won the Best Medical Technology Award at the 2024 Prix Galien USA Awards, often referred to as the 'Nobel Prize of Life Sciences.' The third-generation device, built on Butterfly's proprietary P4.3 semiconductor platform, represents a significant advancement in ultrasound technology with enhanced AI-powered features and digital image capture capabilities. The company's Ultrasound-on-Chip™ technology aims to make ultrasound imaging more affordable, sustainable, and scalable, leveraging Moore's Law to deliver increasingly powerful and cost-effective imaging tools.
Il dispositivo di ultrasound portatile iQ3™ di Butterfly Network ha vinto il Premio per la Migliore Tecnologia Medica agli Awards 2024 Prix Galien USA, spesso definito il 'Premio Nobel delle Scienze della Vita.' Questo dispositivo di terza generazione, basato sulla piattaforma proprietaria P4.3 di Butterfly, rappresenta un significativo progresso nella tecnologia a ultrasuoni, con funzionalità avanzate supportate dall'IA e capacità di cattura di immagini digitali migliorate. La tecnologia Ultrasound-on-Chip™ dell'azienda mira a rendere l'imaging a ultrasuoni più accessibile, sostenibile e scalabile, sfruttando la Legge di Moore per fornire strumenti di imaging sempre più potenti ed economici.
El dispositivo de ultrasonido portátil iQ3™ de Butterfly Network ha ganado el Premio a la Mejor Tecnología Médica en los Premios Prix Galien USA 2024, a menudo denominado el 'Premio Nobel de las Ciencias de la Vida.' Este dispositivo de tercera generación, construido sobre la plataforma semiconductora P4.3 de propiedad de Butterfly, representa un avance importante en la tecnología de ultrasonido, con características mejoradas impulsadas por IA y capacidades de captura de imágenes digitales. La tecnología Ultrasound-on-Chip™ de la empresa tiene como objetivo hacer que la imagenología por ultrasonido sea más asequible, sostenible y escalable, aprovechando la Ley de Moore para ofrecer herramientas de imagenología cada vez más poderosas y rentables.
버터플라이 네트워크의 iQ3™ 휴대용 초음파 기기가 2024 프리 미갈리엔 USA 시상식에서 최고 의료 기술상을 수상했습니다. 이는 종종 '생명 과학의 노벨상'으로 불립니다. 이 제3세대 기기는 버터플라이의 고유 P4.3 반도체 플랫폼을 기반으로 하여 AI 기반 기능과 디지털 이미지 캡처 성능이 향상된 초음파 기술의 중요한 발전을 나타냅니다. 회사의 Ultrasound-on-Chip™ 기술은 초음파 이미지를 보다 저렴하고 지속 가능하며 확장 가능하게 만들기 위해 모어의 법칙을 활용하여 점점 더 강력하고 비용 효율적인 이미징 도구를 제공합니다.
Le dispositif à ultrasons portable iQ3™ de Butterfly Network a remporté le Prix de la Meilleure Technologie Médicale lors des Prix Galien USA 2024, souvent décrit comme le 'Prix Nobel des Sciences de la Vie.' Ce dispositif de troisième génération, basé sur la plateforme semi-conductrice propriétaire P4.3 de Butterfly, représente une avancée significative dans la technologie ultrasonore avec des fonctionnalités améliorées alimentées par l'IA et des capacités de capture d'images numériques. La technologie Ultrasound-on-Chip™ de l'entreprise vise à rendre l'imagerie par ultrasons plus abordable, durable et évolutive, en tirant parti de la Loi de Moore pour offrir des outils d'imagerie de plus en plus puissants et rentables.
Das tragbare Ultraschallgerät iQ3™ von Butterfly Network hat den Preis für die Beste Medizintechnologie bei den Prix Galien USA Awards 2024 gewonnen, die oft als 'Nobelpreis der Lebenswissenschaften' bezeichnet werden. Das Gerät der dritten Generation, das auf der proprietären P4.3 Halbleiterplattform von Butterfly basiert, stellt einen wesentlichen Fortschritt in der Ultraschalltechnik dar, mit verbesserten KI-gestützten Funktionen und digitalen Bildaufnahmefähigkeiten. Die Ultrasound-on-Chip™ Technologie des Unternehmens zielt darauf ab, die Ultraschallbildgebung kostengünstiger, nachhaltiger und skalierbarer zu gestalten, indem sie Moores Gesetz nutzt, um immer leistungsfähigere und kosteneffektivere Bildgebungswerkzeuge bereitzustellen.
- Won prestigious Prix Galien USA Award for Best Medical Technology
- Successfully launched third-generation device (iQ3) with enhanced features
- Proprietary semiconductor technology enables cost-effective scaling
- None.
Insights
The Prix Galien USA Award recognition, while prestigious, does not directly impact Butterfly Network's financial performance or market position. The iQ3 device's technological achievements with its P4.3 semiconductor platform and Ultrasound-on-Chip™ technology demonstrate strong innovation, but awards typically don't translate to immediate business value.
The company's strategy of democratizing ultrasound through portable, semiconductor-based devices shows promise for market expansion. However, with a relatively small
Butterfly Network's Chief Executive Officer, Joseph DeVivo; Co-Founder & VP of Core Technology, Nevada Sanchez; and Chief Strategy Officer, Darius Shahida, accept the Prix Galien
The Galien Foundation was established to foster and reward outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. First created in 1970 in honor of Galien, the father of medical science and modern pharmacology, the Prix Galien Awards have since grown into an influential program convening healthcare stakeholders across industry, science, government and medical press worldwide. The Prix Galien Awards are regarded as the “Nobel Prize of Life Sciences,” and the highest accolade for healthcare research and development.
This prestigious recognition highlights Butterfly’s commitment to making ultrasound imaging more affordable, sustainable, and scalable through its pioneering Ultrasound-on-Chip™ technology. The Butterfly iQ3 represents a leap forward in ultrasound technology, building upon the success of its predecessors with enhanced AI-powered features and novel digital image capture capabilities. Built on Butterfly’s proprietary P4.3 semiconductor – its most powerful Ultrasound-on-Chip™ platform released to date – the iQ3 represents a digital revolution in the ultrasound industry by offering clinicians portable, semiconductor-based imaging with premium handheld quality.
“Winning the Prix Galien Award for Best Medical Technology is an extraordinary testament to the hard work and dedication of our team that brought iQ3 to market this year,” said Joseph DeVivo, President, Chief Executive Officer, and Board Chairman of Butterfly Network. “Our Ultrasound-on-Chip™ technology harnesses the exponential advancements of Moore’s Law, allowing us to deliver increasingly powerful and cost-effective imaging tools. By leveraging this innovation, we are democratizing ultrasound, enabling practitioners everywhere to make faster, more accurate decisions, and ultimately transforming patient care on a global scale.”
Alongside Butterfly, this year’s awardees across various categories includes Pfizer, AstraZeneca, Daiichi Sankyo US, and other highly respected industry leaders.
In today’s announcement, Michael Rosenblatt, MD, Chair of the Prix Galien
Butterfly is honored to be recognized as the Best Medical Technology against a world-class group of nominees. To view the full list of 2024 nominees, visit: https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2024-prix-galien-usa-nominees-for-best-digital-health-solution-best-medical-technology-incubators-accelerators-and-equity-and-best-startup-302220657.html.
About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second-generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108425693/en/
Butterfly Media:
Liz Learned
Head of Corporate Communications, Butterfly
media@butterflynetwork.com
Butterfly Investors:
Heather Getz
Chief Financial and Operations Officers, Butterfly
investors@butterflynetwork.com
Source: Butterfly Network, Inc.
FAQ
What award did Butterfly Network (BFLY) win at the 2024 Prix Galien USA Awards?
What is special about Butterfly Network's (BFLY) iQ3 ultrasound device?
How does Butterfly Network's (BFLY) Ultrasound-on-Chip™ technology work?
